Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas.

Trial Profile

Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Darinaparsin (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 18 Jul 2012 Planned end date changed from 1 Sep 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Planned end date changed from Aug 2009 to Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top